$0.54
-0.10 (-15.42%)
Open$0.64
Previous Close$0.64
Day High$0.64
Day Low$0.52
52W High$1.92
52W Low$0.52
Volume—
Avg Volume536.2K
Market Cap35.03M
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+3,638.5% upside
Current
$0.54
$0.54
Target
$20.24
$20.24
$11.64
$20.24 avg
$22.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.82M | 7.64M | 6.13M |
| Net Income | -1,043,017 | -954,590 | -792,337 |
| Profit Margin | -13.3% | -12.5% | -12.9% |
| EBITDA | -1,028,959 | -906,364 | -702,614 |
| Free Cash Flow | -801,636 | -705,541 | -523,657 |
| Rev Growth | -3.5% | +15.6% | +20.8% |
| Debt/Equity | 1.41 | 1.39 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |